ZERO-MIGRAINE DAYS ARE POSSIBLE

A SIMPLE ONCE-DAILY PILL

Quick and Continuous reductions that last

Across 12 weeks, QULIPTA® 60 mg reduced attacks for both episodic and chronic migraine patients.¹

EM primary endpoint: Significant -4.2 monthly migraine day reduction from 7.8 baseline (n=222; P<0.001) vs -2.5 from 7.5 baseline for placebo (n=214)¹

CM primary endpoint: Significant -6.9 monthly migraine day reduction from 19.2 baseline (n=256; P<0.001) vs -5.1 from 18.9 baseline for placebo
(n=246)¹

NOW APPROVED FOR CHRONIC MIGRAINE

ELIGIBLE COMMERCIALLY INSURED PATIENTS MAY PAY AS LITTLE AS^$0^† A MONTH

*Specific to episodic migraine.

^†Eligibility: Available to patients with commercial insurance coverage for QULIPTA who meet eligibility criteria. This copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs), or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit QULIPTASavingsCard.com or call 1-855-QULIPTA (1-855-785-4782) for more information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy.

^‡Data from Phase 3 ADVANCE EM pivotal study.

^§Data from Phase 3 PROGRESS CM pivotal study.

^¶Data from 52-week, open-label, long term safety study for EM.

CGRP=calcitonin gene-related peptide; CM=chronic migraine; EM=episodic migraine.

Episodic migraine study design (ADVANCE; Phase 2b/3 Dose-finding Study)

Two randomized, double-blind, placebo-controlled, parallel-group studies that evaluated the efficacy and safety of QULIPTA® for 12 weeks in patients who were experiencing 4 to 14 migraine days per month. Patients in trials were 88% female, 80% White, 17% Black, and 12% Hispanic or Latino ethnicity, and the mean age at study entry was 41 years (range 18-74 years). The studies excluded patients with myocardial infarction, stroke, or transient ischemic attacks within 6 months prior to screening.^1,2

Chronic migraine study design (PROGRESS)

A randomized, double-blind, placebo-controlled, parallel-group study that evaluated the efficacy and safety of QULIPTA for 12 weeks in patients who were experiencing 15 or more migraine days per month. Patients in trials were 87% female, 60% White, 3% Black, 36% Asian, and 4% Hispanic or Latino ethnicity, and the mean age at study entry was 42 years (range 18-74 years). A subset of patients (11%) was allowed to use one concomitant migraine preventive medication. The study excluded patients with myocardial infarction, stroke, or transient ischemic attacks within 6 months prior to screening.¹

Open-label, Long-term Safety Study Design

A multicenter, randomized, open-label, 52-week long-term safety study to evaluate the safety and tolerability of QULIPTA 60 mg in participants who experienced 4 to 14 migraine days per month. Participants were randomized to either QULIPTA 60 mg once daily or oral standard-of-care migraine prevention medication. Efficacy variables for long-term efficacy evaluation were not classified as primary, secondary, or additional endpoints. Efficacy measures were only collected for the QULIPTA group. For the 521 participants in the QULIPTA group in the mITT population, mean age was 42.5 years (range 18 to 78 years), 88.3% were female, 76.8% were White, and 15.7% were of Hispanic or Latino ethnicity.³

mITT=modified intention-to-treat.